secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K/A
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-181885
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share
-----------------------------------------------------------------------------

- XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.
- CVR estimated at $0.81 per share, mainly from net cash above $29M; no value assigned to legacy assets.
- Acquired ~$98M in Section 174 tax deductions and legacy LNP assets; no plans for preclinical development.
- Moderna deal has up to ~$1.8B in milestones; next $7.5M milestone not expected within 12 months.
- XOMA will use commercially reasonable efforts for 2 years to monetize legacy IP for CVR holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/0001193125-26-181885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/d229976d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-181885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer